Long-Read Sequencing Services Market Report 2025

The long‑read sequencing services market size has grown rapidly in recent years. It will grow from $0.99 billion in 2024 to $1.18 billion in 2025 at a compound annual growth rate (CAGR) of 19.1%. The growth in the historic period can be linked to rising demand for precision medicine, increased investment in genomics research, growing prevalence of genetic disorders, expanding applications in agricultural genomics, and greater adoption of personalized healthcare.

The long‑read sequencing services market size is expected to see rapid growth in the next few years. It will grow to $2.35 billion in 2029 at a compound annual growth rate (CAGR) of 18.7%. The growth in the forecast period can be linked to rising clinical adoption, higher demand for complex genomic analysis, increased investment in multi-omics research, expanding use in non-human sequencing, and growing collaborations between service providers and pharmaceutical companies. Key trends during the forecast period include advancements in bioinformatic pipelines, development of new sequencing chemistries, innovations in long-read targeted sequencing, progress in integrated multi-omics services, and development of automated sample preparation systems.

The growing prevalence of genetic disorders is expected to drive the expansion of the long-read sequencing services market in the coming years. Genetic disorders are conditions caused by changes or mutations in DNA, which can be inherited or arise spontaneously, affecting various aspects of health, development, or bodily functions. The increasing prevalence of these disorders is attributed to greater awareness and advancements in diagnostic technologies, which allow for earlier and more accurate identification of previously undiagnosed conditions. Long-read sequencing services play a critical role in managing genetic disorders by providing highly accurate, long-range genomic data. This enables precise detection of structural variants and complex mutations, improving diagnostic accuracy, facilitating personalized treatment plans, and enhancing the understanding of rare and inherited diseases. For example, in September 2023, the Cystic Fibrosis Trust reported 11,148 patients diagnosed with cystic fibrosis (CF) in 2022, up from 10,908 in 2021. As a result, the rising prevalence of genetic disorders is driving the growth of the long-read sequencing services market.

Major companies in the long-read sequencing services market are developing innovative solutions, such as high-fidelity sequencing chemistry. This advanced biochemical process combines optimized enzyme systems and nucleotide analogs to generate long-read data with exceptional per-read accuracy, making it ideal for detecting base modifications and structural variants. For instance, in October 2022, Pacific Biosciences of California Inc. launched the Revio long-read sequencing system, which features transformative HiFi sequencing chemistry. This system offers 15 times more HiFi data, enabling the sequencing of hundreds of human genomes per year for under $1,000 each. It addresses critical scalability challenges in genomic research by allowing comprehensive variant detection, including single-nucleotide variants (SNVs), indels, structural variants (SVs), and epigenetic modifications. Additionally, it reduces consumable usage and enhances workflow efficiency.

In February 2022, Element Biosciences Inc., a US-based life sciences company, acquired Loop Genomics Inc. to strengthen its genomic capabilities. Through this acquisition, Element integrated Loop’s synthetic long-read technology into its AVITI platform, expanding its applications across research, clinical, and applied markets. Loop Genomics Inc. is a biotechnology company specializing in long-read sequencing services.

Major players in the long‑read sequencing services market are Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Illumina Inc., Revvity Inc., QIAGEN N.V., BGI Genomics Co. Ltd., Takara Bio Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., GENEWIZ Inc., Macrogen Inc., Novogene Co. Ltd., DNAnexus Inc., Zymo Research Corp., CD Genomics Inc., Genotypic Technology Pvt. Ltd., Plasmidsaurus Inc., BaseClear B.V., GrandOmics Biosciences Co. Ltd., Arima Genomics Inc., and Wuhan Benagen Technology Co. Ltd.

North America was the largest region in the long‑read sequencing services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in long-read sequencing services report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the long-read sequencing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Long-read sequencing services are specialized genomics solutions that generate high-resolution DNA or RNA sequence data by reading long, continuous stretches of nucleotides. These services allow more accurate genome assemblies, identification of structural variations, and analysis of complex genomic regions. They provide deeper insights into genetic makeup, disease mechanisms, and microbial diversity, supporting applications in research, clinical diagnostics, and biopharmaceutical development.

The primary service types of long-read sequencing services include whole genome sequencing, targeted sequencing, de novo sequencing, and others. Whole genome sequencing in long-read sequencing services refers to determining the complete DNA sequence of an organism’s genome in a single continuous read, enabling comprehensive analysis of structural variants and complex regions. The technologies used include single-molecule real-time sequencing, nanopore sequencing, and others, with applications in clinical diagnostics, genomic research, oncology, rare disease detection, and more. End users include academic and research institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and other organizations.

The long‑read sequencing services market research report is one of a series of new reports that provides long‑read sequencing services market statistics, including long‑read sequencing services industry global market size, regional shares, competitors with a long‑read sequencing services market share, detailed long‑read sequencing services market segments, market trends and opportunities, and any further data you may need to thrive in the long‑read sequencing services industry. This long‑read sequencing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The long-read sequencing services market includes revenues earned by entities through target enrichment, metagenomic sequencing, epigenetic modification analysis, microbial genome sequencing, and human leukocyte antigen (HLA) typing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.